Culture medium for culturing vascularized liver organoid, culture method and application

Cultivating vascularized liver organoids on extracellular matrix through specific culture media and methods, solving the problem of difficult isolation and simulation of adult liver tissue and fibrotic environment in the prior art, and achieving accurate simulation and fiber of vascularized liver organoids Application of chemical research.

CN118931818APending Publication Date: 2024-11-12QINGDAO UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411011910.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-26
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing vascularized liver organoid technology cannot isolate primary liver cells, stellate cells and microvessels from the same adult liver tissue for co-culture in vitro, and it is difficult to accurately simulate the environment in which tissue hardening during adult liver tissue and liver fibrosis. , resulting in inability to apply to fibrosis research and drug screening.

Method used

Provides a culture medium and culture method, including basal culture medium and specific additives such as fetal bovine serum, BSA, antibiotics, GSK3 inhibitors and ROCK inhibitors, for culturing adult liver cells on extracellular matrix substrates to form multiple The vascularized liver organoids of the cellular structure of the layer and simulate the tissue hardness changes during fibrosis through extracellular matrix of different softness and hardness.

Benefits of technology

It is realized that primary liver cells, stellate cells and microvascular are isolated from the same adult liver tissue, forming tissue-specific vascularized liver organoids, which can accurately simulate tissue hardening during liver fibrosis, and is suitable for in fibrosis research and drug screening.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118931818A_ABST
    Figure CN118931818A_ABST
Patent Text Reader

Abstract

The invention provides a culture medium for culturing vascularized liver organoid and a culture method and application, and relates to the technical field of biomedicine.The culture medium is composed of a basic culture medium and an additive, BSA is added into the additive, co-culture of microvessels and liver epithelial cells is facilitated, and after the antibiotic concentration is halved, the culture medium can be used for culturing the vascularized liver organoid. And co-culture of microvessels and liver epithelial cells is facilitated. The cell culture medium can be used for culturing cells separated from adult liver tissues, the cells can form a multi-layer cell structure, namely a two-dimensional vascularized liver organoid in a two-dimensional culture dish, and the vascularized liver organoid with different hardness microenvironments is obtained through the action of an extracellular matrix in the culture process. Different stages of tissue hardening in the liver fibrosis process are simulated. The technical problems that in the prior art, an adult liver tissue cannot be accurately simulated through a culture technology of vascularized liver organoid, and the culture technology cannot be applied to fibrosis research and drug screening due to the fact that the tissue hardening environment in the liver fibrosis process cannot be simulated are solved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and in particular to a culture medium for culturing vascularized liver organoids, a culture method and an application thereof. Background Art

[0002] Organoids can simulate organ functions to a certain extent and are used for basic research and drug screening. For example, some studies have reported the use of adult liver cells, embryonic liver cells, embryonic stem cells or induced pluripotent stem cells to construct liver organoids in vitro for disease research. Microvessels play an important role in maintaining the normal functions of organs and tissues and in the occurrence of diseases. The construction of vascularized organoids can better simulate the in vivo microenvironment for basic research and drug screening. There have been some reports on vascular organoid technology, such as the Chinese patent vascularized human adult lung organoids and their construction method with application number 202311381600.2, which discloses the use of vascular progenitor cells differentiated from pluripotent stem cells and human lung organoids to co-culture to form vascularized lung organoids; the Chinese patent organoid culture medium and its application, as well as vascularized liver organoids and their construction method with application number 202211653816.5, discloses the differentiation of pluripotent stem cells into microvascular organoids and liver organoids, and the co-culture of the two to form vascularized liver organoids.

[0003] The existing vascularized liver organoid technology has some shortcomings. For example, the microvessels and liver cells formed by the differentiation of pluripotent stem cells are still somewhat different from the cells in adult tissues. Since each organ has its own specific vascular cell type, the existing pluripotent stem cell differentiation technology is difficult to obtain tissue-specific microvessels and it is difficult to accurately simulate adult liver tissue. In addition, the current vascularized liver organoid technology cannot simulate the environment in which tissue hardens during liver fibrosis, and it is difficult to apply it to fibrosis research and drug screening. Current fibrosis research models generally use artificial synthetic polymers. Although they can better regulate hardness, they still require additional modification of cell adhesion molecules and are not natural extracellular matrices.

[0004] In view of this, the present invention is proposed. Summary of the invention

[0005] One of the purposes of the present invention is to provide a culture medium for culturing vascularized liver organoids, so as to solve the technical problem that the culture medium in the prior art cannot separate primary liver cells, stellate cells and microvessels from the same adult liver tissue for in vitro co-culture to prepare vascularized liver organoids.

[0006] The second purpose of the present invention is to provide a method for culturing vascularized liver organoids to solve the technical problems that the existing culturing technology of vascularized liver organoids is difficult to accurately simulate adult liver tissue and cannot simulate the environment of tissue hardening during liver fibrosis, resulting in the inability to be applied to fibrosis research and drug screening.

[0007] The third object of the present invention is to provide the application of the above-mentioned culture medium or the above-mentioned culture method in screening fibrosis drugs.

[0008] A fourth object of the present invention is to provide a method for screening anti-fibrosis drugs.

[0009] In order to achieve the above-mentioned purpose of the present invention, the following technical solutions are particularly adopted:

[0010] In a first aspect, the present invention provides a culture medium for culturing vascularized liver organoids, which is composed of a basal culture medium and an additive, wherein the additive is composed of the following components in concentrations: 1-20% (v / v) fetal bovine serum, 1-10 mg / ml BSA, 50-100 U / ml penicillin, 50-100 μg / ml streptomycin, 0.125-0.25 μg / ml amphotericin B, 1-20 mM nicotinamide, 1-10 mM N-Acetyl-L-cysteine, 10-100 μM Vitamin C, 1-10 μM glutathione, 1-20 μg / ml insulin, 1-20 μg / ml transferrin, 10-100 nM Sodium Selenite, 5-50 ng / ml vascular endothelial growth factor VEGF, 1-5 μM GSK3 inhibitor, and 5-10 μM ROCK inhibitor;

[0011] The basal culture medium includes DMEM / F12, DMEM or RPMI 1640.

[0012] Furthermore, the GSK3 inhibitor includes Chir99021, SB415286 or CHIR-98014, preferably Chir99021.

[0013] Furthermore, the ROCK inhibitor includes Y27632, SB-772077B or Y-33075, preferably Y27632.

[0014] In a second aspect, the present invention provides a method for culturing vascularized liver organoids, using the above-mentioned culture medium to culture adult liver cells on an extracellular matrix substrate to obtain vascularized liver organoids.

[0015] Furthermore, the method for preparing adult liver cells comprises taking adult liver tissue and performing cyclic digestion to obtain adult liver cells;

[0016] The cyclic digestion comprises the following steps:

[0017] A. Take out the digestion solution containing digested cells every 10 to 20 minutes, collect the cell pellet, add culture medium to resuspend and store for later use, and add new digestion solution to the remaining undigested adult liver tissue;

[0018] B. Repeat step A until all adult liver tissues are digested;

[0019] Preferably, the adult liver tissue has a diameter of 2 to 5 mm;

[0020] Preferably, the digestion condition is 36-38°C digestion, preferably 37°C digestion;

[0021] Preferably, the storage temperature is 0-4°C;

[0022] Preferably, the cyclic digestion further comprises filtering the adult liver cells obtained after the digestion.

[0023] Furthermore, the digestion solution consists of basal culture medium, type I collagenase, DNase, BSA and ROCK inhibitor;

[0024] Preferably, the concentration of type I collagenase in the digestive fluid is 1 to 3 mg / ml, preferably 2 mg / ml;

[0025] Preferably, the concentration of DNase in the digestion solution is 0.01 to 0.2 mg / ml, preferably 0.05 mg / ml;

[0026] Preferably, the concentration of BSA in the digestive fluid is 1 to 10 mg / ml, preferably 5 mg / ml;

[0027] Preferably, the ROCK inhibitor has a median concentration of 1 to 10 μM in the digestive fluid, preferably 5 μM;

[0028] Preferably, the ROCK inhibitor comprises Y27632, SB-772077B or Y-33075, preferably Y27632.

[0029] Furthermore, the culture time is at least 4 days;

[0030] Preferably, the culture conditions include: culturing in an incubator at a constant temperature of 37°C, 95% humidity and 5% CO2;

[0031] Preferably, the culturing further comprises replacing new culture medium every 24 hours.

[0032] In a third aspect, the present invention provides the use of the above-mentioned culture medium or the above-mentioned culture method in screening fibrosis drugs.

[0033] In a fourth aspect, the present invention provides a method for screening anti-fibrosis drugs, comprising the following steps:

[0034] A. preparing fibrotic tissue microenvironment vascularized liver organoids and normal tissue microenvironment vascularized liver organoids using the culture method according to any one of claims 4 to 7;

[0035] B. adding the drug to be screened to the culture medium of the fibrotic tissue microenvironment vascularized liver organoids and the normal tissue microenvironment vascularized liver organoids prepared in step A for co-culturing;

[0036] C. Screen anti-fibrosis drugs based on the expression levels of fibrosis marker genes, microvascular marker genes, and liver epithelial cell marker genes in vascularized liver organoids under fibrotic tissue microenvironment and vascularized liver organoids under normal tissue microenvironment, respectively.

[0037] Further, the step C includes if the expression level of fibrosis marker genes in the vascularized liver organoids under the fibrotic tissue microenvironment is significantly reduced compared with before the addition of the drug to be screened, and the expression levels of microvascular marker genes and liver epithelial cell marker genes in the vascularized liver organoids under the normal tissue microenvironment are not significantly reduced compared with before the addition of the drug to be screened, then the drug to be screened is an anti-fibrosis drug;

[0038] Preferably, the fibrosis marker genes include Col1a1, Col3a1, Acta2 (Sma), Fn1, Fap, Vim, Postn, and Lox;

[0039] Preferably, the liver epithelial cell marker genes include Cdh1 (E-cadherin), Krt8, Krt18, Alb, Krt7, and Krt19;

[0040] Preferably, the hepatic stellate cell marker genes include Desmin (Des), Pdgfrb, and Lrat;

[0041] Preferably, the microvascular marker genes include Apln, Tek, Tie1, Pecam (Cd31), Cdh5, Flt1, Kdr, and Flt4.

[0042] The present invention provides a culture medium for culturing vascularized liver organoids, and the addition of BSA is conducive to the co-culture of microvessels and liver epithelial cells. After the antibiotic concentration is halved, it is conducive to the co-culture of microvessels and liver epithelial cells. It can be used to culture cells separated from adult liver tissue, and these cells can form a multilayer cell structure in a two-dimensional culture dish, wherein the lower layer is epithelial cells and the upper layer is microvessels and stellate cells. This multi-cell culture containing a multilayer structure can be called a two-dimensional vascularized liver organoid. It solves the technical problem that the culture medium in the prior art cannot separate primary liver cells, stellate cells and microvessels from the same adult liver tissue for in vitro co-culture to prepare vascularized liver organoids. On the other hand, a culture method for vascularized liver organoids is provided, in which primary liver cells, stellate cells and microvessels are separated from the same adult liver tissue by the above-mentioned culture medium for in vitro co-culture, and a cell culture extracellular matrix substrate of different hardness is constructed using an extracellular matrix to simulate the change in tissue hardness during fibrosis, and a vascularized liver organoid with a multilayer cell structure grown on a two-dimensional plane is obtained. The vascularized liver organoid not only has tissue-specific microvessels, but also can accurately simulate adult liver tissue, and obtain vascularized liver organoids with microenvironments of different hardness through the action of extracellular matrix to simulate the different stages of tissue hardening during liver fibrosis. Experiments have shown that it can be used for fibrosis research or drug screening. This solves the technical problem that the culturing technology of vascularized liver organoids in the prior art is difficult to accurately simulate adult liver tissue, and cannot simulate the environment of tissue hardening during liver fibrosis, which makes it impossible to apply it to fibrosis research and drug screening. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0044] Figure 1 A schematic diagram of the process flow of the two-dimensional vascularized liver organoid culture method provided by the present invention;

[0045] Figure 2 This is a statistical graph of the expression levels of Cdh1 and Pecam1 in vascularized liver organoids treated with culture media of different concentrations of BSA provided in Example 1 of the present invention;

[0046] Figure 3 A statistical graph of the expression of Ki67 in vascularized liver organoids treated with culture medium containing different concentrations of antibiotics provided in Example 1 of the present invention;

[0047] Figure 4 A statistical graph of the expression of Ki67 in vascularized liver organoids treated with culture media of different concentrations of FBS provided in Example 2 of the present invention;

[0048] Figure 5 A statistical graph of microvessel length in vascularized liver organoids treated with culture medium containing different concentrations of Chir99021 provided in Example 3 of the present invention;

[0049] Figure 6 A statistical graph of microvessel length in vascularized liver organoids treated with culture medium of different concentrations of Y27632 provided in Example 4 of the present invention;

[0050] Figure 7 Bright field photograph of two-dimensional vascularized liver organoids provided for Experiment 2 of the present invention;

[0051] Figure 8 This is a laser confocal microscopic image of immunofluorescence staining of a two-dimensional vascularized liver organoid provided in Experiment 2 of the present invention;

[0052] Fig. 9 The laser confocal microscopic image of the immunofluorescence staining of the two-dimensional vascularized liver organoid provided in Experiment 2 of the present invention shows the superposition (Z projection) after z-axis scanning, as well as the images of the microvascular cells in the upper layer (Top) and the epithelial cells in the lower layer (Bottom);

[0053] Fig.10 Laser confocal microscopic imaging of immunofluorescence staining of two-dimensional vascularized liver organoids provided in Experiment 2 of the present invention, showing images of stellate cells (Desmin) surrounding microvessels (CD31);

[0054] Fig.11 Immunofluorescence staining laser confocal microscopic imaging of fibrotic cells in two-dimensional vascularized liver organoids on extracellular matrix substrates of different hardnesses after A83-01 treatment provided in Experiment 4 of the present invention;

[0055] Fig.12 Immunofluorescence staining laser confocal microscopic imaging of stellate cells in vascularized liver organoids under extracellular matrix substrates of different hardness after A83-01 treatment provided in Experiment 4 of the present invention;

[0056] Fig.13 The expression levels of liver epithelial cell marker genes in vascularized liver organoids under extracellular matrix substrates of different hardness after A83-01 treatment provided in Experiment 4 of the present invention;

[0057] Fig.14The expression levels of stellate cell marker genes in vascularized liver organoids under extracellular matrix substrates of different hardness after A83-01 treatment provided in Experiment 4 of the present invention;

[0058] Fig.15 The expression levels of fibrosis marker genes in vascularized liver organoids under extracellular matrix substrates of different hardness after A83-01 treatment provided in Experiment 4 of the present invention;

[0059] Fig.16 The expression levels of microvascular marker genes in vascularized liver organoids under extracellular matrix substrates of different hardness after A83-01 treatment provided in Experiment 4 of the present invention;

[0060] Fig.17 The expression levels of fibrosis marker genes in vascularized liver organoids under extracellular matrix substrates of different hardness after pirfenidone treatment provided in Experiment 4 of the present invention;

[0061] Fig.18 The expression levels of microvascular marker genes in vascularized liver organoids under extracellular matrix substrates of different hardness after pirfenidone treatment provided in Experiment 4 of the present invention. DETAILED DESCRIPTION

[0062] Unless otherwise defined herein, scientific and technical terms used in conjunction with the present invention shall have the meanings commonly understood by those of ordinary skill in the art. The meaning and scope of the terms should be clear, however, in the case of any potential ambiguity, the definitions provided herein take precedence over any dictionary or external definitions. In this application, unless otherwise stated, the use of "or" means "and / or". In addition, the use of the term "including" and other forms is non-limiting.

[0063] The methods and techniques of the present invention are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated.

[0064] In one aspect, the present invention provides a culture medium for culturing vascularized liver organoids, which is composed of a basal culture medium and an additive, wherein the additive is composed of the following components in concentrations: 1-20% (v / v) fetal bovine serum, 1-10 mg / ml BSA, 50-100 U / ml penicillin, 50-100 μg / ml streptomycin, 0.125-0.25 μg / ml amphotericin B, 1-20 mM nicotinamide, 1-10 mM N-Acetyl-L-cysteine, 10-100 μM Vitamin C, 1-10 μM glutathione, 1-20 μg / ml insulin, 1-20 μg / ml transferrin, 10-100 nM Sodium Selenite, 5-50 ng / ml vascular endothelial growth factor VEGF, 1-5 μM GSK3 inhibitor, and 5-10 μM ROCK inhibitor;

[0065] The basal culture medium includes DMEM / F12, DMEM or RPMI 1640.

[0066] Experiments have shown that the addition of BSA is beneficial to the co-culture of microvessels and liver epithelial cells. When the antibiotic concentration is halved, it is beneficial to the co-culture of microvessels and liver epithelial cells. The use of amphotericin B can inhibit fungal growth. The culture medium can be used to culture adult liver tissue, from which a multilayer cell structure is separated, in which the lower layer is epithelial cells, and the upper layer is microvessels and stellate cells (such as Figure 1 The multilayer cell structure can be cultured to obtain vascularized liver organoids. The technical problem that the culture medium in the prior art cannot separate primary liver cells, stellate cells and microvessels from the same adult liver tissue for in vitro co-culture to prepare vascularized liver organoids is solved.

[0067] The concentration of the fetal bovine serum may be, but is not limited to, 1%, 2%, 4%, 6%, 8%, 10%, 12%, 14%, 16%, 18% or 20%, or any value between 1 and 20%.

[0068] The concentration of the BSA (bovine serum albumin) can be, but is not limited to, 1 mg / ml, 2 mg / ml, 3 mg / ml, 4 mg / ml, 5 mg / ml, 6 mg / ml, 7 mg / ml, 8 mg / ml, 9 mg / ml or 10 mg / ml, and can also be any value between 1 and 10 mg / ml.

[0069] The concentration of the antibiotic can be 50U / ml penicillin, 50μg / ml streptomycin, 0.125μg / ml amphotericin B, or 100U / ml penicillin, 100μg / ml streptomycin, 0.25μg / ml amphotericin B, preferably: 50U / ml penicillin, 50μg / ml streptomycin, 0.125μg / ml amphotericin B.

[0070] The nicotinamide is an amide form of water-soluble vitamin B3, and its concentration can be, but not limited to, 1mM, 2mM, 4mM, 6mM, 8mM, 10mM, 12mM, 14mM, 16mM, 18mM or 20mM, or any value between 1 and 20mM. The N-Acetyl-L-cysteine ​​can have a concentration of, but not limited to, 1mM, 2mM, 3mM, 4mM, 5mM, 6mM, 7mM, 1mM, 9mM or 10mM, or any value between 1 and 10mM. The concentration of Vitamin C can be, but not limited to, 10μM, 20μM, 30μM, 40μM, 50μM, 60μM, 70μM, 80μM, 90μM or 100μM, or any value between 10 and 100μM. The concentration of the glutathione may be, but is not limited to, 1 μM, 2 μM, 3 μM, 4 μM, 5 μM, 6 μM, 7 μM, 8 μM, 9 μM or 10 μM, or any value between 1 and 10 μM. The concentration of the insulin may be, but is not limited to, 1 μg / ml, 2 μg / ml, 4 μg / ml, 6 μg / ml, 8 μg / ml, 10 μg / ml, 12 μg / ml, 14 μg / ml, 16 μg / ml, 18 μg / ml or 20 μg / ml, or any value between 1 and 20 μg / ml. The concentration of transferrin can be, but is not limited to, 1 μg / ml, 2 μg / ml, 4 μg / ml, 6 μg / ml, 8 μg / ml, 10 μg / ml, 12 μg / ml, 14 μg / ml, 16 μg / ml, 18 μg / ml or 20 μg / ml, or any value between 1 and 20 μg / ml. The concentration of sodium selenite can be, but is not limited to, 10 nM, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, 90 nM or 100 nM, or any value between 10 and 100 nM. The concentration of the vascular endothelial growth factor VEGF can be, but is not limited to, 5ng / ml, 10ng / ml, 15ng / ml, 20ng / ml, 25ng / ml, 30ng / ml, 35ng / ml, 40ng / ml, 45ng / ml or 50ng / ml, or any value between 5 and 50ng / ml. The concentration of the GSK3 inhibitor can be, but is not limited to, 1μM, 2μM, 3μM, 4μM or 5μM, or any value between 1 and 5μM. The concentration of the ROCK inhibitor can be, but is not limited to, 5μM, 6μM, 7μM, 8μM, 9μM or 10μM, or any value between 5 and 10μM.

[0071] In some specific embodiments, the GSK3 inhibitor includes Chir99021, SB415286 or CHIR-98014, preferably Chir99021.

[0072] In some specific embodiments, the ROCK inhibitor comprises Y27632, SB-772077B or Y-33075, preferably Y27632.

[0073] According to another aspect of the present invention, a method for culturing vascularized liver organoids is also provided, wherein the above-mentioned culture medium is used to culture adult liver cells on an extracellular matrix substrate to obtain vascularized liver organoids.

[0074] Primary liver cells, stellate cells and microvessels are separated from the same adult liver tissue by the above-mentioned culture medium for in vitro co-culture, and the cell culture extracellular matrix substrate with different hardness is constructed using the extracellular matrix to simulate the change of tissue hardness during fibrosis, and a vascularized liver organoid with a multilayer cell structure grown on a two-dimensional plane is obtained. The vascularized liver organoid not only has tissue-specific microvessels, but also can accurately simulate adult liver tissue, and obtains vascularized liver organoids with different hardness microenvironments through the action of the extracellular matrix to simulate the different stages of tissue hardening during liver fibrosis. Experiments have shown that it can be used for fibrosis research or drug screening. It solves the technical problem that the culture technology of vascularized liver organoids in the prior art is difficult to accurately simulate adult liver tissue, and it is impossible to simulate the environment of tissue hardening during liver fibrosis, which makes it impossible to apply to fibrosis research and drug screening. Among them, the extracellular matrix substrate adopts the collagen matrix culture dish disclosed in the Chinese patent application number 2023106567683.

[0075] In some specific embodiments, the method for preparing adult liver cells comprises taking adult liver tissue and performing cyclic digestion to obtain adult liver cells; the cyclic digestion comprises the following steps:

[0076] A. Take out the digestion solution containing digested cells every 10 to 20 minutes, collect the cell pellet, add culture medium to resuspend and store for later use, and add new digestion solution to the remaining undigested adult liver tissue;

[0077] B. Repeat step A until all adult liver tissues are digested.

[0078] By processing adult liver tissue in a cyclic digestion manner and collecting cell pellets every 10 to 20 minutes, the damage of the digestive fluid to the cells can be reduced and the activity of adult liver cells can be improved.

[0079] In some specific embodiments, the obtained adult liver tissue can be cut into pieces with a diameter of 2 to 5 mm to facilitate digestion, shorten the digestion time, and reduce the damage of the digestive juice to the cells.

[0080] In some specific embodiments, the digestion condition is 36-38°C digestion, preferably 37°C digestion. The digestion can be performed in an incubator set at 36-38°C, or in a water bath at 36-38°C.

[0081] In some specific embodiments, the storage temperature is 0-4°C. Specifically, the resuspended cells can be placed on ice and stored at a low temperature of 0-4°C to maintain cell viability.

[0082] In some specific embodiments, the cyclic digestion further comprises filtering the adult liver cells obtained after digestion. Specifically, the cell suspension can be filtered through a 30-micron filter to remove impurities and red blood cells, and the cell components on the filter can be collected.

[0083] In some specific embodiments, the digestion solution consists of basal culture medium, type I collagenase, DNase, BSA and ROCK inhibitor.

[0084] In some specific embodiments, the concentration of the type I collagenase in the digestive fluid is 1 to 3 mg / ml. The concentration of the type I collagenase in the digestive fluid may be, but is not limited to, 1 mg / ml, 1.2 mg / ml, 1.4 mg / ml, 1.6 mg / ml, 1.8 mg / ml, 2 mg / ml, 2.2 mg / ml, 2.4 mg / ml, 2.6 mg / ml, 2.8 mg / ml or 3 mg / ml, or any concentration value between 1 and 3 mg / ml, preferably 2 mg / ml.

[0085] In some specific embodiments, the concentration of the DNA enzyme in the digestion solution is 0.01-0.2 mg / ml. The concentration of the DNA enzyme in the digestion solution may be, but is not limited to, 0.01 mg / ml, 0.02 mg / ml, 0.05 mg / ml, 0.1 mg / ml, 0.15 mg / ml or 0.2 mg / ml, or any concentration value between 0.01 and 0.2 mg / ml, preferably 0.05 mg / ml.

[0086] In some specific embodiments, the concentration of BSA in the digestive juice can be but is not limited to 1 mg / ml, 2 mg / ml, 3 mg / ml, 4 mg / ml, 5 mg / ml, 6 mg / ml, 7 mg / ml, 8 mg / ml, 9 mg / ml or 10 mg / ml, and can be any concentration value between 1 and 10 mg / ml, preferably 5 mg / ml.

[0087] In some specific embodiments, the concentration of the ROCK inhibitor in the basal medium is 1 to 10 μM. The concentration of the ROCK inhibitor in the basal medium may be any concentration value, but is not limited to, 1 μM, 2 μM, 3 μM, 4 μM, 5 μM, 6 μM, 7 μM, 8 μM, 9 μM or 10 μM, or any concentration value between 1 and 10 μM, preferably 5 μM.

[0088] In some specific embodiments, the ROCK inhibitor includes Y27632, SB-772077B or Y-33075, preferably Y27632.

[0089] In some specific embodiments, the culture time is at least 4 days, and vascularized liver organoids can be formed.

[0090] In some specific embodiments, the culture conditions include: culturing in an incubator at a constant temperature of 37° C., 95% humidity, and 5% CO 2 .

[0091] In some specific embodiments, the culture further comprises replacing new culture medium every 24 hours.

[0092] According to another aspect of the present invention, there is also provided the use of the above culture medium or the above culture method in screening fibrosis drugs.

[0093] According to another aspect of the present invention, a method for screening anti-fibrosis drugs is also provided, comprising the following steps:

[0094] A. Using the above culture method to prepare vascularized liver organoids in a fibrotic tissue microenvironment and vascularized liver organoids in a normal tissue microenvironment respectively;

[0095] B. adding the drug to be screened to the culture medium of the vascularized liver organoids in the fibrotic tissue microenvironment and the vascularized liver organoids in the normal tissue microenvironment prepared in step A for co-culturing;

[0096] C. Screen anti-fibrosis drugs based on the expression levels of fibrosis marker genes, microvascular marker genes, and liver epithelial cell marker genes in vascularized liver organoids under fibrotic tissue microenvironment and vascularized liver organoids under normal tissue microenvironment, respectively.

[0097] By evaluating the effects of the drugs to be screened on the expression levels of fibrosis marker genes, microvascular marker genes and liver epithelial cell marker genes in vascularized liver organoids in fibrotic tissue microenvironment and normal tissue microenvironment, the anti-fibrosis effect and side effects of the drugs to be screened can be achieved.

[0098] In some specific embodiments, step C includes if the expression level of fibrosis marker genes in the vascularized liver organoids under the fibrotic tissue microenvironment is significantly reduced compared with before the addition of the drug to be screened, and the expression levels of microvascular marker genes and liver epithelial cell marker genes in the vascularized liver organoids in the normal tissue microenvironment are not significantly reduced compared with before the addition of the drug to be screened, then it indicates that the drug to be screened is a potential anti-fibrosis drug with fewer side effects.

[0099] When the expression of fibrosis genes in the vascularized liver organoids with fibrotic tissue microenvironment is significantly reduced, it can be shown that the drug to be screened has the effect of inhibiting fibrosis genes, while the expression of microvascular marker genes and liver epithelial cell marker genes in the vascularized liver organoids with normal tissue microenvironment is not significantly reduced, indicating that the drug to be screened has less effect on non-fibrosis marker genes, that is, less side effects. If the drug to be screened inhibits the expression of epithelial cell or microvascular cell marker genes, it indicates that it has potential side effects.

[0100] In some specific embodiments, the fibrosis marker genes include at least two of Col1a1, Col3a1, Acta2 (Sma), Fn1, Fap, Vim, Postn and Lox;

[0101] In some specific embodiments, the liver epithelial cell marker genes include at least two of Cdh1 (E-cadherin), Krt8, Krt18, Alb, Krt7 and Krt19;

[0102] In some specific embodiments, the hepatic stellate cell marker genes include at least two of Desmin (Des), Pdgfrb and Lrat;

[0103] In some specific embodiments, the microvascular marker genes include at least two of Apln, Tek, Tie1, Pecam (Cd31), Cdh5, Flt1, Kdr and Flt4.

[0104] In some specific embodiments, the co-culture time in step B is at least 7 days, and the control group can form relatively obvious fibrosis characteristics on day 7, including fibrosis marker gene expression and protein staining.

[0105] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0106] The reagents used in the following examples are as follows:

[0107] Basal culture medium: purchased from Shanghai Yuanpei Biotechnology Co., Ltd.; fetal bovine serum (FBS): purchased from Shanghai Yuanpei Biotechnology Co., Ltd.; amphotericin B: purchased from Shanghai Yuanpei Biotechnology Co., Ltd.; Nicotinamide: purchased from Sigma; N-Acetyl-L-cysteine: purchased from Sigma; VEGF: purchased from Peprotech; Chir99021: purchased from Selleck; Y27632: purchased from Selleck; type I collagenase: purchased from Worthington; DNase: purchased from Worthington; BSA: purchased from Sigma.

[0108] Example 1: Method for culturing vascularized liver organoids

[0109] 1. Culture medium with different concentrations of BSA;

[0110] The culture medium includes DMEM / F12, 2% (v / v) fetal bovine serum, 100U / ml penicillin, 100μg / ml streptomycin, 0.25μg / ml amphotericin B, 5mM nicotinamide, 1mM N-Acetyl-L-cysteine, 50μM Vitamin C, 3μM glutathione, 10μg / ml insulin, 7.5μg / ml transferrin, 40nM Sodium Selenite, 10ng / ml vascular endothelial growth factor VEGF, 2μM Chir99021 and 5μM Y27632. Based on this culture medium, 1mg / ml, 2mg / ml, 5mg / ml and 10mg / ml BSA are added to obtain culture medium containing different concentrations of BSA.

[0111] 2. Culture medium with different concentrations of antibiotics;

[0112] The culture medium includes DMEM / F12, 2% (v / v) fetal bovine serum, 5 mg / ml BSA, 5 mM nicotinamide, 1 mM N-Acetyl-L-cysteine, 50 μM Vitamin C, 3 μM glutathione, 10 μg / ml insulin, 7.5 μg / ml transferrin, 40 nM Sodium Selenite, 10 ng / ml vascular endothelial growth factor VEGF, 2 μM Chir99021 and 5 μM Y27632. Based on this culture medium, treatments including addition of 50 U / ml penicillin, 50 μg / ml streptomycin and 0.125 μg / ml amphotericin B, treatments including addition of 75 U / ml penicillin, 75 μg / ml streptomycin and 0.1875 μg / ml amphotericin B, and treatments including addition of 100 U / ml penicillin, 100 μg / ml streptomycin and 0.25 μg / ml amphotericin B were set up respectively.

[0113] 3. Culture methods of vascularized liver organoids:

[0114] (1) Adult liver tissue was cut into 2 mm pieces and digested in a digestive enzyme solution. The digestive enzyme composition was as follows: DMEM, 2 mg / ml type I collagenase, 0.05 mg / ml DNase, 5 mg / ml BSA, and 5 μM Y27632.

[0115] (2) Digest tissue using the cyclic digestion method: digest the tissue in a 37-degree water bath, gently shake to accelerate the digestion process, take out the digestion solution every 10 minutes, which contains the digested cells, centrifuge to collect the cell pellet, add culture medium to the centrifuge tube to resuspend the cells, and place the cell suspension centrifuge tube on ice to maintain a low temperature of 0-4°C to preserve cell viability. Suspension, add fresh digestion solution to the remaining tissue blocks and continue digestion at 37 degrees. After 10 minutes, take out the digestion solution again and centrifuge to collect the cells. Repeat this process until all tissue blocks are digested.

[0116] (3) Collect all cell suspensions, remove impurities and red blood cells through a 30-micron filter, and collect the cell components on the filter.

[0117] (4) Using the culture medium containing different concentrations of BSA prepared in the above 1 and the culture medium containing different concentrations of antibiotics prepared in the above 2, respectively, the cells obtained in step (3) are cultured on an extracellular matrix substrate with a hardness of 3 GPa, wherein the preparation process of the extracellular matrix substrate is as follows: adding 0.1 mg / ml extracellular matrix solution to a culture dish to cover the bottom of the culture dish, aspirating the extracellular matrix solution after 1 hour, washing the culture dish once with PBS, and then using it to inoculate cells for culture experiments.

[0118] (5) Vascularized liver organoids were formed after 4 days of culture.

[0119] 4. Detection

[0120] The vascularized liver organoids treated with culture media with different concentrations of BSA and culture media with different concentrations of antibiotics obtained in the three cultures were used to detect the expression levels of liver epithelial cell marker genes Cdh1 and Pecam1 and cell proliferation marker gene Ki67 using the qPCR method. The specific results are as follows Figure 2 and Figure 3 As shown, One-way ANOVA was used for statistical analysis, * represents P < 0.05, where Figure 2 The expression statistics of Cdh1 and Pecam1 in vascularized liver organoids treated with culture medium of different BSA concentrations are shown in Figure 2. Figure 3 Shown is a statistical graph of changes in Ki67 expression in vascularized liver organoids under treatment with culture medium containing different concentrations of antibiotics.

[0121] like Figure 2 As shown in the figure, the expression levels of Cdh1 and Pecam1 in the treatment with BSA added were higher than those in the treatment without BSA added, and the expression levels of Cdh1 and Pecam1 in the treatment with 5mg / ml and 10mg / ml BSA concentrations were significantly higher than those in the treatment without BSA added. The expression level of Cdh1 was the highest in the treatment with 5mg / ml BSA concentration, and the expression level of Pecam1 was no different from that in the treatment with 10mg / ml BSA concentration. Therefore, the BSA concentration is preferably 5mg / ml. Figure 3 As shown, the expression level of Ki67 in the treatment with triple antibodies was higher than that in the treatment with double antibodies. It can be seen that triple antibody treatment can promote cell proliferation, among which the treatment with 50U / ml penicillin, 50μg / ml streptomycin and 0.125μg / ml amphotericin B was the best.

[0122] Example 2

[0123] Different from Example 1, the cells obtained in step (3) were cultured on an extracellular matrix substrate with a hardness of 3 GPa using the following culture medium. The culture medium includes DMEM / F12, 5 mg / ml BSA, 50 U / ml penicillin, 50 μg / ml streptomycin, 0.125 μg / ml amphotericin B, 20 mM nicotinamide, 6 mM N-Acetyl-L-cysteine, 100 μM Vitamin C, 7 μM glutathione, 1 μg / ml insulin, 20 μg / ml transferrin, 100 nM Sodium Selenite, 50 ng / ml vascular endothelial growth factor VEGF, 2 μM Chir99021 and 5 μM Y27632. Based on this culture medium, different concentrations of FBS were added, including different treatments of 2%, 10% and 20%.

[0124] Example 3

[0125] Different from Example 1, the cells obtained in step (3) were cultured on an extracellular matrix substrate with a hardness of 3 GPa using the following culture medium. The culture medium included DMEM / F12, 2% (v / v) fetal bovine serum, 5 mg / ml BSA, 50 U / ml penicillin, 50 μg / ml streptomycin, 0.125 μg / ml amphotericin B, 10 mM nicotinamide, 10 mM N-Acetyl-L-cysteine, 10 μM Vitamin C, 10 μM glutathione, 20 μg / ml insulin, 1 μg / ml transferrin, 10 nM Sodium Selenite, 30 ng / ml vascular endothelial growth factor VEGF and 10 μM Y27632. Based on this culture medium, different concentrations of Chir99021 were added, including different treatments of 1 μM, 2 μM and 5 μM.

[0126] Example 4

[0127] Different from Example 1, the cells obtained in step (3) were cultured on an extracellular matrix substrate with a hardness of 3 GPa using the following culture medium. The culture medium included DMEM / F12, 2% (v / v) fetal bovine serum, 5 mg / ml BSA, 50 U / ml penicillin, 50 μg / ml streptomycin, 0.125 μg / ml amphotericin B, 5 mM nicotinamide, 1 mM N-Acetyl-L-cysteine, 50 μM Vitamin C, 3 μM glutathione, 10 μg / ml insulin, 7.5 μg / ml transferrin, 40 nM Sodium Selenite, 10 ng / ml vascular endothelial growth factor VEGF and 2 μM Chir99021. Based on this culture medium, different concentrations of Y27632 were added, including different treatments of 1 μM, 2 μM, 5 μM and 10 μM.

[0128] The optimized culture medium includes DMEM / F12, 2% (v / v) fetal bovine serum, 5 mg / ml BSA, 50 U / ml penicillin, 50 μg / ml streptomycin, 0.125 μg / ml amphotericin B, 5 mM nicotinamide, 1 mM N-Acetyl-L-cysteine, 50 μM Vitamin C, 3 μM glutathione, 10 μg / ml insulin, 7.5 μg / ml transferrin, 40 nM Sodium Selenite, 10 ng / ml vascular endothelial growth factor VEGF, 2 μM Chir99021 and 5 μM Y27632.

[0129] Experiment 1

[0130] The qPCR method was used to detect and analyze the expression level of the proliferation marker gene Ki67 in the vascularized liver organoids cultured in Example 2 and the relative length of the microvessels in the vascularized liver organoids in Example 3 and Example 4. The specific results are as follows: Figures 4 to 6 As shown, statistical analysis was performed using One-way ANOVA, where *P<0.05, **P<0.01, ***P<0.001.

[0131] like Figure 4 It can be seen that after the FBS concentration increased from 2% to 10% and 20%, the expression of Ki67 only increased to about 1.2 times of the original. From an economic point of view, 2% FBS is a better choice and can achieve the purpose of culturing vascularized liver organoids. The length of microvessels increased with the increase of Chir99021 or Y27632 addition, such as Figure 5As shown in Figure 2, when the amount of Chir99021 added exceeded 2 μM, the plateau phase was reached. Figure 6 As shown, a plateau phase was reached when the amount of Y27632 added exceeded 5 μM. Therefore, the amount of Chir99021 added to the culture medium was preferably 2 μM, and the amount of Y27632 added was preferably 5 μM.

[0132] Experiment 2 Characterization of vascularized liver organoids

[0133] The vascularized liver organoids cultured in the culture medium optimized in Example 1 according to the culture method described in 3 of Example 1 were fixed with paraformaldehyde, permeabilized with 0.1% Triton X-100 solution, incubated with primary antibody for 2 hours, washed 3 times with PBS, incubated with secondary antibody for 1 hour, and then incubated with DAPI to label the cell nuclei. Finally, the samples were sealed and observed by immunofluorescence staining and laser confocal microscopy. The specific results are as follows: Figure 7 to Figure 10 As shown, Figure 8 The middle cross-sectional image shows that the bottom layer (Bottom) is the epithelial cells positively stained with E-cadherin, and the top layer (Top) is the vascular endothelial cells positively stained with CD31. The primary antibodies used are shown in Table 1.

[0134] Table 1

[0135] Antibody factory source serial number Dilution ratio CD31 Affinity Goat AF3628 1:200 E-cadherin Proteintech Rabbit 20874-1-AP 1:300 αSMA Santa Cruz Mouse SC32251 1:400 Desmin Proteintech Rabbit 16520-1-AP 1:200 CollagenⅠ Affinity Rabbit AF7001 1:100

[0136] Experiment 3: Simulating the microenvironment at different stages of liver fibrosis

[0137] The culture medium optimized in Example 1 was selected and cultured on the surface of the extracellular matrix substrate with different hardness according to the culture method described in 3 of Example 1, specifically, the hardness was set to 3 GPa, 20 kPa, 6 kPa and 1 kPa in sequence to obtain vascularized liver organoids under the extracellular matrix substrates with different hardness.

[0138] The preparation method of the 1 kPa substrate includes: placing 8 mg / ml of extracellular matrix gel in a 37-degree incubator for half an hour, and the gel is naturally formed, and the Young's modulus of the gel surface is about 1 kPa.

[0139] The preparation method of the 20kPa substrate includes: adding 2.075ml of 0.5mg / ml extracellular matrix solution into a 35mm culture dish, evenly covering the bottom of the culture dish, and slowly drying and dehydrating in a 37°C drying oven for 3 days to obtain a substrate with a Young's modulus of approximately 20kPa.

[0140] The preparation method of the 6kPa substrate includes: adding 4.15ml of 1.25mg / ml extracellular matrix solution into a 35mm culture dish, evenly covering the bottom of the culture dish, and slowly drying and dehydrating in a 37°C drying oven for 3 days to obtain a substrate with a Young's modulus of approximately 6kPa.

[0141] Experiment 4 Testing Anti-fibrotic Drugs

[0142] (1) Experiment 3 was used to obtain vascularized liver organoids under extracellular matrix substrates of different hardnesses. TGFβ signaling pathway inhibitor A83-01 was added to the culture medium for co-culture for 7 days. A control group without A83-01 was set up. Immunofluorescence staining and laser confocal microscopy were used to observe the expression of fibrosis marker SMA in vascularized liver organoids under extracellular matrix substrates of 3 GPa and 1 kPa hardnesses. Fig.11 and Fig.12 As shown, antibodies targeting CD31, Desmin, and SMA were used, respectively, and the scale bar is 100 μm.

[0143] like Fig.11 As shown in the figure, on the surface of the substrate with a hardness of 3GPa, the vascularized liver organoids expressed the fibrosis marker SMA. After adding the TGFβ signaling pathway inhibitor A83-01, it can be seen that there is still a certain amount of SMA expression; on the surface of the extracellular matrix gel at 1kPa, A83-01 can significantly inhibit SMA expression. Fig.12 As shown, it can be seen that on the surface of 1 kPa extracellular matrix gel, A83-01 inhibits the fibrosis marker SMA while still retaining a certain amount of astrocytes.

[0144] The expression levels of liver epithelial cell marker genes (Cdh1, Krt8, Krt18, Alb, Krt7 and Krt19), stellate cell marker genes (Des, Pdgfrb and Lrat), fibrosis marker genes (Col1a1, Col3a1, Acta2 (Sma), Fn1, Fap, Vim, Postn and Lox) and microvascular marker genes (Apln, Tek, Tie1, Pecam (Cd31), Cdh5, Flt1, Kdr and Flt4) in vascularized liver organoids under extracellular matrix of different hardness were detected by qPCR method. The primer list used is shown in 2.

[0145] Table 2

[0146]

[0147]

[0148] The experimental results are as follows Figure 13 to Figure 16As shown. It can be seen that the regulatory effect of A83-01 on microvascular marker genes is affected by the hardness of the substrate. It upregulates microvascular marker genes on a hard substrate and inhibits their expression on a soft substrate. This indicates that the regulatory effect of A83-01 on liver microvessels is affected by the hardness of the extracellular matrix substrate, that is, the degree of liver fibrosis affects the effect of anti-fibrosis drugs.

[0149] (2) Pirfenidone, a drug approved by the FDA for the treatment of pulmonary fibrosis, was selected as the drug to be screened instead of the TGFβ signaling pathway inhibitor A83-01 and added to the culture medium. The expression levels of fibrosis marker genes and microvascular marker genes in vascularized liver organoids under extracellular matrix substrates of different hardness were detected by qPCR. Fig.17 and Fig.18 shown.

[0150] It can be seen that pirfenidone can significantly inhibit the fibrosis genes Col1a1 and Col3a1, but has little effect on microvascular-related genes on the soft substrate, which means that the drug has less impact on normal tissues, that is, it has fewer side effects.

[0151] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A culture medium for culturing vascularized liver organoids, It is characterized in that The invention is composed of a basic culture medium and an additive, wherein the additive is composed of the following components in the following concentrations: 1-20% (v / v) fetal bovine serum, 1-10 mg / ml BSA, 50-100 U / ml penicillin, 50-100 μg / ml streptomycin, 0.125-0.25 μg / ml amphotericin B, 1-20 mM nicotinamide, 1-10 mM N-Acetyl-L-cysteine, 10-100 μM Vitamin C, 1-10 μM glutathione, 1-20 μg / ml insulin, 1-20 μg / ml transferrin, 10-100 nM Sodium Selenite, 5-50 ng / ml vascular endothelial growth factor VEGF, 1-5 μM GSK3 inhibitor and 5-10 μM ROCK inhibitor; The basal culture medium includes DMEM / F12, DMEM or RPMI 1640.

2. The culture medium according to claim 1, It is characterized in that The GSK3 inhibitor includes Chir99021, SB415286 or CHIR-98014, preferably Chir99021.

3. The culture medium according to claim 1, It is characterized in that ROCK inhibitors include Y27632, SB-772077B or Y-33075, preferably Y27632.

4. A method for culturing vascularized liver organoids, It is characterized in that Adult liver cells are cultured on an extracellular matrix substrate using the culture medium according to any one of claims 1 to 3 to obtain vascularized liver organoids.

5. The culture method according to claim 4, It is characterized in that The method for preparing adult liver cells comprises taking adult liver tissue and performing cyclic digestion to obtain adult liver cells; The cyclic digestion comprises the following steps: A. Take out the digestion solution containing digested cells every 10 to 20 minutes, collect the cell pellet, add culture medium to resuspend and store for later use, and add new digestion solution to the remaining undigested adult liver tissue; B. Repeat step A until all adult liver tissues are digested; Preferably, the adult liver tissue has a diameter of 2 to 5 mm; Preferably, the digestion condition is 36-38°C digestion, preferably 37°C digestion; Preferably, the storage temperature is 0-4°C; Preferably, the cyclic digestion further comprises filtering the adult liver cells obtained after the digestion.

6. The culture method according to claim 5, It is characterized in that The digestion solution consists of a basic culture medium, type I collagenase, DNase, BSA, and ROCK inhibitor; Preferably, the basal culture medium is DMEM / F12, DMEM or RPMI 1640, preferably DMEM; Preferably, the concentration of type I collagenase in the digestive fluid is 1 to 3 mg / ml, preferably 2 mg / ml; Preferably, the concentration of the DNA enzyme in the digestion solution is 0.01-0.2 mg / ml, preferably 0.05 mg / ml; Preferably, the concentration of BSA in the digestive fluid is 1 to 10 mg / ml, preferably 5 mg / ml; Preferably, the concentration of the ROCK inhibitor in the digestive fluid is 1 to 10 μM, preferably 5 μM; Preferably, the ROCK inhibitor comprises Y27632, SB-772077B or Y-33075, preferably Y27632.

7. The culture method according to claim 6, It is characterized in that The culture time is at least 4 days; Preferably, the culture conditions include: a constant temperature of 37°C, 95% humidity and 5% CO 2 Cultured in an incubator; Preferably, the culturing further comprises replacing new culture medium every 24 hours.

8. Use of the culture medium according to any one of claims 1 to 3 or the culture method according to any one of claims 4 to 7 in screening fibrosis drugs.

9. A method for screening anti-fibrosis drugs, It is characterized in that The following steps are involved: A. preparing fibrotic tissue microenvironment vascularized liver organoids and normal tissue microenvironment vascularized liver organoids using the culture method according to any one of claims 4 to 7; B. adding the drug to be screened to the culture medium of the fibrotic tissue microenvironment vascularized liver organoids and the normal tissue microenvironment vascularized liver organoids prepared in step A for co-culturing; C. Screen anti-fibrosis drugs based on the expression levels of fibrosis marker genes, microvascular marker genes, and liver epithelial cell marker genes in vascularized liver organoids under fibrotic tissue microenvironment and vascularized liver organoids under normal tissue microenvironment, respectively.

10. The method according to claim 9, It is characterized in that The step C includes: if the expression level of fibrosis marker genes in the vascularized liver organoids under the fibrotic tissue microenvironment is significantly reduced compared with that before the addition of the drug to be screened, and the expression levels of microvascular marker genes and liver epithelial cell marker genes in the vascularized liver organoids under the normal tissue microenvironment are not significantly reduced compared with that before the addition of the drug to be screened, then the drug to be screened is an anti-fibrosis drug; Preferably, the fibrosis marker genes include at least two of Col1a1, Col3a1, Acta2 (Sma), Fn1, Fap, Vim, Postn and Lox; Preferably, the liver epithelial cell marker genes include at least two of Cdh1 (E-cadherin), Krt8, Krt18, Alb, Krt7 and Krt19; Preferably, the hepatic stellate cell marker genes include at least two of Desmin (Des), Pdgfrb and Lrat; Preferably, the microvascular marker genes include at least two of Apln, Tek, Tie1, Pecam (Cd31), Cdh5, Flt1, Kdr and Flt4; Preferably, the co-cultivation time in step B is at least 7 days.

Citation Information

Cited By

  • Co-differentiated vascularized liver organ and construction method thereof

    CN120158421A